Merck -- called MSD outside of Canada and the United States -- recently announced that its representatives will present data from the company’s clinical development programs for broad chronic hepatitis C virus (HCV) infections.
These presentations, given at the International Liver Congress 2016, include the results taken from the company’s phase-three study of the Zepatier treatment, which includes elbasvir and grazoprevir. The study compares this drug to a regimen that contains sofosbuvir.
The study specifically evaluates 50-milligram and 100-milligram tablets of the treatment. These are included in the phase-three C-Edge Head-to-Head trial. There will also be details from the phase-three C-Edge IBLD and C-Edge Co-Star studies, which determine whether Zepatier is efficient in patients who are underserved because of their illnesses that are difficult to treat.
In addition, representatives will present other information about people who have diseases that are difficult to treat.
“We continue to build on the data that supported the recent U.S. FDA approval of Zepatier with additional studies that provide clinical evidence about Zepatier in multiple patient populations,” Dr. Eliav Barr, vice president of infectious diseases for Merck Research Laboratories, said. “Merck remains committed to the fight against chronic hepatitis C through our ongoing clinical programs exploring diverse patient groups and areas of unmet need.”
